AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25474427 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 576
Study 25474427 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin and placebo
Number of subjects: 576
Study 22627795 — intervention group
Group type: EXPERIMENTAL
Intervention: CTP (CT perfusion) group
Number of subjects: 36
Study 22627795 — intervention group
Group type: COMPARATOR
Intervention: Stroke scale group (NIHSS with NCCT and CTA)
Number of subjects: 36
Study 21041921 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine 200 mg twice daily
Number of subjects: 1203
Study 21041921 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1203
Study 18581020 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track group (continuous infusion of fentanyl and propofol, atracurium one hour later)
Number of subjects: 100
Study 18581020 — intervention group
Group type: COMPARATOR
Intervention: Conventional extubation group (bolus doses of fentanyl and pancuronium)
Number of subjects: 100
Study 15858063 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (selective alpha2‐adrenoceptor antagonist)
Number of subjects: 0
Study 15858063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11798991 — intervention group
Group type: EXPERIMENTAL
Intervention: Throwing group (professional pitchers)
Number of subjects: 50
Study 11798991 — intervention group
Group type: COMPARATOR
Intervention: Nonthrowing group (control)
Number of subjects: 50
Study 11798991 — intervention group
Group type: COMPARATOR
Intervention: Comparison of dominant shoulders
Number of subjects: 50
Study 10527088 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary training program for rheumatoid arthritis
Number of subjects: 68
Study 7697926 — intervention group
Group type: EXPERIMENTAL
Intervention: gp120-depleted, inactivated HIV-1 antigen in incomplete Freund's adjuvant (IFA; HIV-1 Immunogen)
Number of subjects: 0
Study 7697926 — intervention group
Group type: COMPARATOR
Intervention: IFA alone
Number of subjects: 0
Study 2014355 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable method for theophylline measurement
Number of subjects: 69
Study 2014355 — intervention group
Group type: COMPARATOR
Intervention: Conventional laboratory-based analysis
Number of subjects: 69
Study 7018051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinoxacin 250 mg four times a day (QID)
Number of subjects: 91
Study 7018051 — intervention group
Group type: COMPARATOR
Intervention: Cinoxacin 500 mg twice a day (BID)
Number of subjects: 91
Study 30182128 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-reporting of FIM motor score
Number of subjects: 33
Study 30182128 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-reporting of individual motor items
Number of subjects: 33
Study 30182128 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary assessment of FIM motor score
Number of subjects: 33
Study 28342227 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP-I 1.0% and dexamethasone 0.1%
Number of subjects: 78
Study 28342227 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.1%
Number of subjects: 78
Study 28342227 — intervention group
Group type: COMPARATOR
Intervention: Lubricating eyedrops (hypromellose 0.3%)
Number of subjects: 78
Study 25904734 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Committee (HC) group
Number of subjects: 55
Study 25904734 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 23269120 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA infants
Number of subjects: 367
Study 23269120 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower mean birth weight z-score
Number of subjects: 367
Study 21749850 — intervention group
Group type: EXPERIMENTAL
Intervention: Water infusion
Number of subjects: 116
Study 21749850 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 116
Study 18270378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty (CBA)
Number of subjects: 43
Study 18270378 — intervention group
Group type: COMPARATOR
Intervention: Conventional percutaneous transluminal angioplasty (PTA)
Number of subjects: 43
Study 18270378 — intervention group
Group type: COMPARATOR
Intervention: PTA
Number of subjects: 43
Study 18270378 — intervention group
Group type: EXPERIMENTAL
Intervention: CBA
Number of subjects: 43
Study 16527031 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast
Number of subjects: 0
Study 16527031 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 0
Study 16527031 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine and pseudoephedrine
Number of subjects: 0
Study 16527031 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12883303 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil emulsion
Number of subjects: 45
Study 12883303 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil emulsion
Number of subjects: 45
Study 11044477 — intervention group
Group type: EXPERIMENTAL
Intervention: Succimer
Number of subjects: 780
Study 11044477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780
Study 9325952 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement mattress
Number of subjects: 0
Study 9325952 — intervention group
Group type: COMPARATOR
Intervention: Static air mattress
Number of subjects: 0
Study 8238122 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU of oxytocin in 20 ml of normal saline solution
Number of subjects: 50
Study 8238122 — intervention group
Group type: COMPARATOR
Intervention: 20 ml of normal saline solution (placebo)
Number of subjects: 50
Study 3321878 — intervention group
Group type: EXPERIMENTAL
Intervention: carteolol 1%
Number of subjects: 20
Study 3321878 — intervention group
Group type: COMPARATOR
Intervention: carteolol 2%
Number of subjects: 20
Study 29653645 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 2203
Study 29653645 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 2203
Study 28401136 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacy-based case finding and intervention
Number of subjects: 48
Study 26609282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ashwagandha (300 mg twice daily)
Number of subjects: 57
Study 24023317 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade with zoledronic acid (CAB-ZA)
Number of subjects: 60
Study 24023317 — intervention group
Group type: COMPARATOR
Intervention: Combined androgen blockade (CAB)
Number of subjects: 60
Study 21149436 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sugar cereals
Number of subjects: 91
Study 21149436 — intervention group
Group type: COMPARATOR
Intervention: Low-sugar cereals
Number of subjects: 91
Study 18328090 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg once daily
Number of subjects: 3032
Study 18328090 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg twice daily
Number of subjects: 3032
Study 18328090 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg once daily
Number of subjects: 3032
Study 16888080 — intervention group
Group type: EXPERIMENTAL
Intervention: SHiDo chemotherapy
Number of subjects: 129
Study 16888080 — intervention group
Group type: COMPARATOR
Intervention: CHOP chemotherapy
Number of subjects: 129
Study 12741348 — intervention group
Group type: EXPERIMENTAL
Intervention: Menotropin treatment for three months (Group A)
Number of subjects: 60
Study 12741348 — intervention group
Group type: EXPERIMENTAL
Intervention: Menotropin treatment starting three months after surgery (Group B)
Number of subjects: 60
Study 12741348 — intervention group
Group type: COMPARATOR
Intervention: Varicocelectomy only (Group C)
Number of subjects: 60
Study 10971538 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser assisted uvulopalatoplasty (LAUP)
Number of subjects: 47
Study 10971538 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional uvulopalatopharyngoplasty (UPPP)
Number of subjects: 47
Study 10971538 — intervention group
Group type: COMPARATOR
Intervention: Comparison of LAUP and UPPP
Number of subjects: 47
Study 8835649 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine or fluvoxamine (intervention)
Number of subjects: 30
Study 8835649 — intervention group
Group type: COMPARATOR
Intervention: N/A (control group not specified)
Number of subjects: 30
Study 1411848 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-day split dose of 1.6 g of metronidazole
Number of subjects: 132
Study 1411848 — intervention group
Group type: COMPARATOR
Intervention: Single 2-g dose of tinidazole
Number of subjects: 132
Study 3907725 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 40
Study 3907725 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expectations of meditation
Number of subjects: 40
Study 3907725 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 40
Study 30937447 — intervention group
Group type: EXPERIMENTAL
Intervention: Short pre-travel consultation (8-12 minutes) with smartphone support
Number of subjects: 149
Study 30937447 — intervention group
Group type: COMPARATOR
Intervention: Standard length pre-travel consultation (18-22 minutes)
Number of subjects: 149
Study 29106665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks (NIVO3)
Number of subjects: 40
Study 29106665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for 4 doses (NIVO1+IPI3)
Number of subjects: 40
Study 29106665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 3 weeks for 4 doses (NIVO3+IPI1)
Number of subjects: 40
Study 26911520 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC) + primary percutaneous coronary intervention (pPCI)
Number of subjects: 129
Study 26911520 — intervention group
Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (pPCI) alone
Number of subjects: 129
Study 24673834 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer-determined physical activity (PA)
Number of subjects: 560
Study 24673834 — intervention group
Group type: COMPARATOR
Intervention: Self-reported health
Number of subjects: 560
Study 23001752 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 44
Study 23001752 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 44
Study 20705290 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day mifepristone and misoprostol regimen
Number of subjects: 100
Study 20705290 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day mifepristone and misoprostol regimen
Number of subjects: 100
Study 18263997 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast health messages administered by salon stylists
Number of subjects: 1210
Study 18263997 — intervention group
Group type: COMPARATOR
Intervention: Control salons (no messages)
Number of subjects: 1210
Study 16080872 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (3.75 mg injected intramuscularly every 28 days for 3 months)
Number of subjects: 125
Study 16080872 — intervention group
Group type: COMPARATOR
Intervention: Leuprorelin (3.75 mg injected subcutaneously every 28 days for 3 months)
Number of subjects: 125
Study 12435290 — intervention group
Group type: EXPERIMENTAL
Intervention: CVAP + docetaxel (100 mg/m2)
Number of subjects: 162
Study 10355669 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdural electrodes made of platinum
Number of subjects: 9
Study 10355669 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp recording
Number of subjects: 9
Study 10355669 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizure control after resection of the cortex
Number of subjects: 9
Study 7577853 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg danazol daily (n = 17)
Number of subjects: 36
Study 7577853 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg gestrinone twice weekly (n = 19)
Number of subjects: 36
Study 7682931 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.25‐0.75 mg, intramuscular)
Number of subjects: 8
Study 7682931 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.50 and 0.75 mg, intramuscular)
Number of subjects: 8
Study 2947098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Number of subjects: 10
Study 2947098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29996980 — intervention group
Group type: EXPERIMENTAL
Intervention: PRPFM treatment group
Number of subjects: 76
Study 29996980 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study 29996980 — intervention group
Group type: EXPERIMENTAL
Intervention: PRPFM technique
Number of subjects: 76
Study 29996980 — intervention group
Group type: COMPARATOR
Intervention: Double-row technique (control)
Number of subjects: 76
Study 26086792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin 2 mg daily
Number of subjects: 86
Study 26086792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 24296517 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose calcium lactate (300 mg · kg(‐1) body mass)
Number of subjects: 22
Study 24296517 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose calcium lactate (150 mg · kg(‐1) body mass)
Number of subjects: 22
Study 24296517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 22728514 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of intestinal microbiota from lean donors
Number of subjects: 0
Study 22728514 — intervention group
Group type: COMPARATOR
Intervention: Autologous microbiota infusion
Number of subjects: 0
Study 20508469 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermogenic drink (TD) - 336 mL daily
Number of subjects: 60
Study 20508469 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) - 336 mL daily
Number of subjects: 60
Study 18232610 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of Personal Digital Assistants (PDAs) during clinical education
Number of subjects: 0
Study 18232610 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used)
Number of subjects: 0
Study 16405713 — intervention group
Group type: EXPERIMENTAL
Intervention: tTG-based ELISA
Number of subjects: 204
Study 16405713 — intervention group
Group type: EXPERIMENTAL
Intervention: eTG-based ELISA
Number of subjects: 204
Study 12627313 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (3 x 500 mg tablets daily for 7 days prior to race and 150 mg/l in carbohydrate beverages during race)
Number of subjects: 28
Study 12627313 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 tablets daily for 7 days prior to race and no vitamin C in carbohydrate beverages during race)
Number of subjects: 28
Study 12627313 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Vitamin C and Placebo)
Number of subjects: 28
Study 12627313 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 28
Study 9666526 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (Praxilene)
Number of subjects: 30
Study 9666526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8291920 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg)
Number of subjects: 107
Study 8291920 — intervention group
Group type: COMPARATOR
Intervention: Granisetron plus MPL (10 mg/kg)
Number of subjects: 107
Study 8291920 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron alone
Number of subjects: 107
Study 8291920 — intervention group
Group type: COMPARATOR
Intervention: Granisetron plus MPL
Number of subjects: 107
Study 3174217 — intervention group
Group type: EXPERIMENTAL
Intervention: Stryker Constavac
Number of subjects: 45
Study 3174217 — intervention group
Group type: COMPARATOR
Intervention: Snyder Hemovac
Number of subjects: 45
Study 5787671 — intervention group
Group type: EXPERIMENTAL
Intervention: LB46, 0.5 mg by oral administration
Number of subjects: 0
Study 5787671 — intervention group
Group type: COMPARATOR
Intervention: Propranolol, 20 mg
Number of subjects: 0
Study 29467598 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina extract (1500 mg for 6 weeks)
Number of subjects: 19
Study 29467598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 29122251 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at LI4 and HT7 points
Number of subjects: 90
Study 29122251 — intervention group
Group type: COMPARATOR
Intervention: Sham pressure
Number of subjects: 90
Study 29122251 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 90
Study 26595965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous laser irradiation in addition to traditional medicamental therapy (Group 2)
Number of subjects: 120
Study 26595965 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser skin treatment (Group 3)
Number of subjects: 120
Study 26595965 — intervention group
Group type: COMPARATOR
Intervention: Traditional medicamental therapy alone (Control Group 1)
Number of subjects: 120
Study 23307840 — intervention group
Group type: EXPERIMENTAL
Intervention: FLF24 (24 h fermented liquid feed)
Number of subjects: 240
Study 23307840 — intervention group
Group type: EXPERIMENTAL
Intervention: FLF48 (48 h fermented liquid feed)
Number of subjects: 240
Study 23307840 — intervention group
Group type: COMPARATOR
Intervention: CON (dry basal feed)
Number of subjects: 240
Study 21178603 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (n=80)
Number of subjects: 256
Study 21178603 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=77)
Number of subjects: 256
Study 21178603 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 256
Study 21178603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 18477182 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat meal (3.1 MJ, 742 kcal, 75.8% fat)
Number of subjects: 5
Study 18477182 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate meal (3.3 MJ, 794 kcal, 77.5% carbohydrate)
Number of subjects: 5
Study 18477182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietetic advice
Number of subjects: 5
Study 17070147 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive LDL-C reduction (goal <70 mg/dL)
Number of subjects: 549
Study 17070147 — intervention group
Group type: COMPARATOR
Intervention: Standard LDL-C reduction (goal <100 mg/dL)
Number of subjects: 549
Study 17070147 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive BP reduction (goal <115/75 mm Hg)
Number of subjects: 549
Study 17070147 — intervention group
Group type: COMPARATOR
Intervention: Standard BP reduction (goal <130/85 mm Hg)
Number of subjects: 549
Study 17070147 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary end points include carotid plaque score, left ventricular geometry and function, serum C-reactive protein, and safety measures.
Number of subjects: 549
Study 13677262 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 0
Study 13677262 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined immunosuppressive treatment (antithymocyte globulin, methylprednisolone, and cyclosporine)
Number of subjects: 0
Study 10862065 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine 0.1 mmol/kg
Number of subjects: 30
Study 10862065 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine 0.2 mmol/kg
Number of subjects: 30
Study 10862065 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Number of subjects: 30
Study 10021716 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine surfactant prophylaxis (200 mg/kg endotracheally)
Number of subjects: 53
Study 10021716 — intervention group
Group type: COMPARATOR
Intervention: Routine assistance (Control)
Number of subjects: 53
Study 8498878 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 30
Study 8498878 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 30
Study 8498878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3691610 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg trimetazidine (single dose)
Number of subjects: 0
Study 3691610 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg trimetazidine (chronic administration, three times a day)
Number of subjects: 0
Study 29861018 — intervention group
Group type: EXPERIMENTAL
Intervention: Apligraf
Number of subjects: 0
Study 29861018 — intervention group
Group type: COMPARATOR
Intervention: TheraSkin
Number of subjects: 0
Study 27468128 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fructose diet (HFrD) (+3.5 g fructose/kg fat-free mass per day) for 7 days
Number of subjects: 10
Study 27468128 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fructose diet (HFrD)
Number of subjects: 10
Study 27468128 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro experiments in human myotubes
Number of subjects: 10
Study 25910661 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position during colonoscope withdrawal on the right side of the colon
Number of subjects: 130
Study 25910661 — intervention group
Group type: COMPARATOR
Intervention: Supine position during colonoscope withdrawal on the left side of the colon
Number of subjects: 130
Study 24296342 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial exercises (daily training for 7 weeks)
Number of subjects: 18
Study 24296342 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 18
Study 20650362 — intervention group
Group type: EXPERIMENTAL
Intervention: Short door-to-balloon time (DBT) (<= 90 min)
Number of subjects: 4548
Study 20650362 — intervention group
Group type: EXPERIMENTAL
Intervention: Short DBT (<= 90 min) in early presentation
Number of subjects: 4548
Study 20650362 — intervention group
Group type: EXPERIMENTAL
Intervention: Short DBT (<= 90 min) in later presentation
Number of subjects: 4548
Study 20650362 — intervention group
Group type: EXPERIMENTAL
Intervention: Short DBT (<= 90 min) in high-risk patients
Number of subjects: 4548
Study 20650362 — intervention group
Group type: EXPERIMENTAL
Intervention: Short DBT (<= 90 min) in low-risk patients
Number of subjects: 4548